Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes

Click here to view online. Add this email to your safelist.

26 August 2021

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.